Novartis CEO cites political influence in FDA drug review

09/28/2007 | Financial Times (tiered subscription model)

Political pressure to address drug safety controversies has made the FDA overcautious in reviewing new drugs for approval, Novartis AG CEO Daniel Vasella said in a conference on Friday. Two drugs in Novartis' pipeline, the diabetes drug Galvus and the painkiller Prexige, recently have met significant regulatory delays with the FDA.

View Full Article in:

Financial Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN